CAT 5571
Alternative Names: CAT-5571Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Catabasis Pharmaceuticals
- Developer Astria Therapeutics; Bill & Melinda Gates Medical Research Institute
- Class Antifibrotics; Docosahexaenoic acids; Small molecules
- Mechanism of Action Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cystic fibrosis; Tuberculosis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Tuberculosis in USA (PO)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (PO)
- 08 Sep 2021 Catabasis Pharmaceuticals is now called Astria Therapeutics